Together, these data suggest that HGF/c-Met pathway inhibition may overcome resistance to anti-EGFR therapy in R/M HNSCC, such as in patients with clinical cetuximab resistance. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.